These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 22017273)

  • 21. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review.
    Buttini MJ; Jordan SJ; Webb PM
    Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):316-22. PubMed ID: 19566568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
    Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).
    Sangkomkamhang US; Lumbiganon P; Pattanittum P
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD008994. PubMed ID: 33226133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.
    Varma R; Sinha D; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):9-28. PubMed ID: 16325993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effects of different treatments based on the levonorgestrel intrauterine system in endometrial carcinoma and endometrial hyperplasia patients: a network meta-analysis.
    Tao M; Wu T; Zhou X; Du X; Ling K; Liang Z
    Arch Gynecol Obstet; 2024 Sep; 310(3):1315-1329. PubMed ID: 38980346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
    Elassall GM; Sayed EG; Abdallah NA; El-Zohiry MM; Radwan AA; AlMahdy AM; Sedik AS; Elazeem HASA; Shazly SA
    J Gynecol Obstet Hum Reprod; 2022 Oct; 51(8):102432. PubMed ID: 35760334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.
    Morelli M; Di Cello A; Venturella R; Mocciaro R; D'Alessandro P; Zullo F
    Gynecol Endocrinol; 2013 Feb; 29(2):156-9. PubMed ID: 23134558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS).
    Heikinheimo O; Gemzell-Danielsson K
    Acta Obstet Gynecol Scand; 2012 Jan; 91(1):3-9. PubMed ID: 22007693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
    Krashin J; Tang JH; Mody S; Lopez LM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
    Conz L; Mota BS; Bahamondes L; Teixeira Dória M; Françoise Mauricette Derchain S; Rieira R; Sarian LO
    Acta Obstet Gynecol Scand; 2020 Aug; 99(8):970-982. PubMed ID: 31990981
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
    Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
    Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
    Ørbo A; Arnes M; Vereide AB; Straume B
    BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia.
    van der Meer AC; Hanna LS
    Clin Obes; 2017 Feb; 7(1):54-57. PubMed ID: 27984850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia.
    Bian J; Shao H; Liu H; Li H; Fang L; Xing C; Wang L; Tao M
    Reprod Sci; 2015 Jun; 22(6):758-66. PubMed ID: 25536958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant endometrial polyp in woman with the levonorgestrel intrauterine system - a case report.
    Kuzel D; Mara M; Zizka Z; Koliba P; Dundr P; Fanta M
    Gynecol Endocrinol; 2019 Feb; 35(2):112-114. PubMed ID: 30449212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
    Wildemeersch D; Janssens D; Weyers S
    Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Why perimenopausal women should consider to use a levonorgestrel intrauterine system.
    Wildemeersch D
    Gynecol Endocrinol; 2016 Aug; 32(8):659-661. PubMed ID: 26930021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.